{"id":153957,"name":"ENZYVANT THERAPEUTICS GMBH","slug":"enzyvant-therapeutics-gmbh","state":"MA","country":"United States of America","description":"Biopharmaceutical company","totalSpending":700000,"filings":25,"yearlySpending":[{"year":2018,"income":130000},{"year":2019,"income":120000},{"year":2020,"income":120000},{"year":2021,"income":120000},{"year":2022,"income":120000},{"year":2023,"income":90000},{"year":2024,"income":0}],"issues":["HCR","MMM"],"firms":["JEFFREY J. KIMBELL & ASSOCIATES, INC."],"lobbyists":["JEFFREY KIMBELL","JOHN HERZOG","JODIE LOCKHART","KENNETH HODGE","KEITH STUDDARD","JOHN RAY","DAVID RUDLOFF","KELSEY CARLSON"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Office of Management & Budget (OMB)","SENATE","Food & Drug Administration (FDA)"],"sampleDescriptions":["Pharmaceutical and healthcare issues","Pharmaceutical and healthcare issues","Education about rare disease therapies","Education about rare disease therapies","Education about rare disease therapies"],"years":[2018,2019,2020,2021,2022,2023,2024]}